Poland· PL-100439069
Piqray
A alpelisib product containing alpelisibum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 12 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Alpelisib is registered in 12 of 19 countries.
Countries holding a registration under ATC L01EM03 (alpelisib), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Alpelisib · ATC L01EM03
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of alpelisib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alpelisib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$136.30
The record
At a glance
URPL (Poland)- Active substance
- Alpelisibum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- L01EM03
- ATC class
- Alpelisib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin07613421024840
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
347 interactions on record for alpelisib.
Graded by severity as the source publishes them — 14 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Alpelisib · interactions on record
347 records
- 14 severe
- 329 moderate
- 4 minor
Most severe, free to view
- EdoxabanB01AF03severe
- RifampicinJ04AB02severe
- RifabutinJ04AB04severe
- RifapentineJ04AB05severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Alpelisib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandPiqray 200 mg + 50 mg, FilmtablettenNovartis Pharma Schweiz AG
- CzechiaPIQRAYNovartis Europharm Limited, Dublin
- NetherlandsPiqray 200 mg filmomhulde tablettenNovartis Europharm Limited
- NorwayPiqrayNovartis Europharm Limited (1)
- IrelandPiqray 200 mg film-coated tabletsNovartis Europharm Limited
- IcelandPiqrayNovartis Europharm Limited*
- BelgiumPiqray 200 mgNovartis Europharm
- SwedenPiqray 200 mg Filmdragerad tablettNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Piqray, Vijoice
- Liechtenstein · Piqray, Vijoice
- Norway · Piqray, Vijoice
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/b3d35dd1-4c9f-42d2-b321-d54a7a58e5c7 GET /v1/drugs/b3d35dd1-4c9f-42d2-b321-d54a7a58e5c7?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "200 mg",
"packaging": "Rpz ¦ EU/1/20/1455/007 ¦ 137158\n14 tabl.\n07613421024840 ¦ Rpz ¦ EU/1/20/1455/008 ¦ 137159\n28 tabl.\nRpz ¦ EU/1/20/1455/009 ¦ 137160\n84 tabl.",
"substance": "Alpelisibum 200 mg",
"common_name": "Alpelisibum",
"pl_product_id": "100439069",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about alpelisib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.